These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37872109)

  • 1. Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice.
    Miyake T; Mochizuki T; Nakagawa T; Nakamura M; Emoto C; Komiyama N; Hirabayashi M; Tsuruta S; Shimojo T; Terao K; Tachibana T
    Br J Pharmacol; 2024 Apr; 181(7):1091-1106. PubMed ID: 37872109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
    Nakada N; Kawamura A; Kamimura H; Sato K; Kazuki Y; Kakuni M; Ohbuchi M; Kato K; Tateno C; Oshimura M; Usui T
    Biopharm Drug Dispos; 2016 Jan; 37(1):3-14. PubMed ID: 26352195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver.
    Kato K; Ohbuchi M; Hamamura S; Ohshita H; Kazuki Y; Oshimura M; Sato K; Nakada N; Kawamura A; Usui T; Kamimura H; Tateno C
    Drug Metab Dispos; 2015 Aug; 43(8):1208-17. PubMed ID: 25979261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4.
    Jiang P; Chen T; Chu LF; Xu RP; Gao JT; Wang L; Liu Q; Tang L; Wan H; Li M; Ren HC
    Expert Opin Drug Metab Toxicol; 2023; 19(10):721-731. PubMed ID: 37746740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Utility of PXB Chimeric Mice for Predicting Human Liver Partitioning of Hepatic Organic Anion-Transporting Polypeptide Transporter Substrates.
    Feng B; Pemberton R; Dworakowski W; Ye Z; Zetterberg C; Wang G; Morikawa Y; Kumar S
    Drug Metab Dispos; 2021 Mar; 49(3):254-264. PubMed ID: 33376106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver.
    Uchida M; Tajima Y; Kakuni M; Kageyama Y; Okada T; Sakurada E; Tateno C; Hayashi R
    Drug Metab Dispos; 2018 Jan; 46(1):11-19. PubMed ID: 29051147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Chimeric Mice with Humanized Livers for Predicting Hepatic Organic Anion-Transporting Polypeptide 1B-Mediated Clinical Drug-Drug Interactions.
    Feng B; Liang G; Zetterberg C; Li S; Huang H; Williams J; Gao H; Morikawa Y; Kumar S
    Drug Metab Dispos; 2024 Sep; 52(10):1073-1082. PubMed ID: 39103225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
    Lu C; Hatsis P; Berg C; Lee FW; Balani SK
    Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
    Sanoh S; Horiguchi A; Sugihara K; Kotake Y; Tayama Y; Ohshita H; Tateno C; Horie T; Kitamura S; Ohta S
    Drug Metab Dispos; 2012 Feb; 40(2):322-8. PubMed ID: 22048522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.
    Rioux N; Bellavance E; Bourg S; Garneau M; Ribadeneira MD; Duan J
    Biopharm Drug Dispos; 2013 Oct; 34(7):396-401. PubMed ID: 23873286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.
    Ly JQ; Messick K; Qin A; Takahashi RH; Choo EF
    Mol Pharm; 2017 May; 14(5):1754-1759. PubMed ID: 28345929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
    Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
    AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.